Search results
Novavax Stock Just Tripled. Is It Too Late to Buy?
Motley Fool via Yahoo Finance· 1 day agoThe Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. Novavax Stock Just...
Moderna says FDA delaying decision on RSV vaccine approval, shares fall
Investing.com· 6 days agoModerna says FDA delaying decision on RSV vaccine approval, shares fall
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 23 hours agoLike other early-stage biotech companies, Gyre has reported years of annual losses, though came in...
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Benzinga via Yahoo Finance· 14 minutes agoOn Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical...
FDA Delays Decision on Moderna RSV Shot by 3 Weeks
Barrons.com· 6 days agoThe agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the drug’s safety, efficacy, or...
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Investor's Business Daily· 2 days agoNovavax will also receive tiered royalties on sales. Sanofi also made a $70 million investment in...
Stocks Log Weekly Gains in Hot Start to May
The Wall Street Journal· 6 days agoThe S&P 500 inched 0.2% higher, while the tech-heavy Nasdaq Composite edged a hair lower. The May performance marks a reversal from April, when...
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors
Guru Focus· 2 days agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
Stock Market News for May 14, 2024
Zacks via Yahoo Finance· 2 days agoAverage (DJI) fell 0.2% or 81.33 points to close at 39,431.51. Notably, 13 components of the 30-stock index ended in negative territory, while 17...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks· 3 days agoFree Report) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345.
